Invited Cancer Treatment Review Describes Novel in Situ Cancer Vaccine to Cure Recurrent Cancer
Steps to Clinical Trials are Considered for Generex/Antigen Express Product
15-Apr-2004 -
Toronto. Generex Biotechnology Corporation , announced the publication of an invited review in Cancer Treatment Reviews. This paper, by Antigen Express scientists and collaborators, describes their preclinical data supporting a novel and patented mechanism to induce presentation of a full ...
antigens
autoimmune diseases
biochemistry
+13